U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839092) titled 'Prophylactic PIPAC in Patients with High-risk Colorectal Cancer' on Feb. 16.
Brief Summary: In patients with colorectal cancer at high risk for metachronous peritoneal carcinomatosis (pT4 pN0-2 cM0 pMMR colorectal cancer of the colon, colorectal junction or high rectum and/or with positive cytology), we will compare standard surgery (consisting in removal of the primary cancer) followed by 3 months of adjuvant chemotherapy + 3 cycles of oxaliplatin-based PIPAC (4-6 weeks apart), to standard surgery followed by 3 months of adjuvant systemic chemotherapy, in terms of 1-year peritoneal metastasis-free survival, 3-year.
Study Start Dat...